Previous 10 |
home / stock / brrgf / brrgf news
BERGEN, Norway , April 9, 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class drug candidates targeting AXL kinase to treat aggressive diseases including immune-evasive and therapy resistant cancers,...
BerGenBio ASA ( OTCPK:BRRGF ) has dosed first patient in an additional cohort ("Cohort B") of an ongoing Phase II open-label study of selective AXL inhibitor bemcentinib in combination with Merck's (NYSE: MRK ) anti-PD-1 therapy KEYTRUDA (pembrolizumab) in previously treated pati...
- First patient dosed in new cohort of Phase II trial evaluating selective AXL inhibitor bemcentinib in combination with KEYTRUDA in patients with advanced NSCLC whose disease is progressing on anti-PD(L)1 therapy - New cohort added under existing collaborative agreement with Merck asses...
Extensive data in pre-clinical models of non-small cell lung cancer (NSCLC) and pancreatic cancer demonstrating AXL's role in reversing tumour-mediated immunosuppression and therapy resistance presented at AACR Selective AXL inhibitor, bemcentinib, shown to reverse AXL's effects, thus act...
The year 2019 is an exciting time for Rigel Pharmaceuticals ( RIGL ) in many ways and not so much in others. On the one hand, the company will generate its first full year of sales data from Tavalisse (fostamatinib) which it began marketing for chronic immune thrombocytopenia ((ITP)) in late...
BergenBio ( OTCPK:BRRGF ): Q4 GAAP EPS of -NOK0.93. More news on: BergenBio AS ORD, Earnings news and commentary, Healthcare stocks news, , Read more ...
BERGEN, Norway , Feb. 12, 2019 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces its results for the fourth quarter and full year 2018. A presentation ...
News, Short Squeeze, Breakout and More Instantly...
Brent Resources Group Ltd Company Name:
BRRGF Stock Symbol:
OTCMKTS Market:
Brent Resources Group Ltd Website:
Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting Encouraging updated preliminary survival data more than double standard of care reported in relapsed AML patients PR Newswire BERGEN, Norway ...
BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020 BERGEN, Norway , Dec. 6, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL...
BerGenBio Presents Phase II Bemcentinib Combination Study in NSCLC at Annual SITC Meeting PR Newswire BERGEN, Norway, Nov. 11, 2020 BERGEN, Norway , Nov. 11, 2020 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing...